ACE Inhibitors News and Research

RSS
ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

Polypill could reduce CVD and stroke in Latin Americans by up to 21% at lower cost

Polypill could reduce CVD and stroke in Latin Americans by up to 21% at lower cost

Left ventricular systolic dysfunction prevalent in at-risk inpatients

Left ventricular systolic dysfunction prevalent in at-risk inpatients

NSAID–antihypertensive combinations may risk kidney damage

NSAID–antihypertensive combinations may risk kidney damage

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive therapy touted for obese

BMI may influence which blood pressure treatments work best

BMI may influence which blood pressure treatments work best

ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction

ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction

Leading allergy organizations release report that sheds light on angioedema

Leading allergy organizations release report that sheds light on angioedema

Canadian Cardiovascular Society issues new pediatric heart failure guidelines

Canadian Cardiovascular Society issues new pediatric heart failure guidelines

Gender gap in myocardial infarction mortality

Gender gap in myocardial infarction mortality

New treatment target brings hope for scleroderma patients

New treatment target brings hope for scleroderma patients

Surprising new roles for angiotensin converting enzyme

Surprising new roles for angiotensin converting enzyme

Type 2 diabetics with normoalbuminuria more likely to develop heart problems

Type 2 diabetics with normoalbuminuria more likely to develop heart problems

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Eplerenone shown to reduce cumulative heart failure hospitalisations

Eplerenone shown to reduce cumulative heart failure hospitalisations

Spinal cord stimulation could become novel treatment option for heart failure

Spinal cord stimulation could become novel treatment option for heart failure

Insulin glargine retards progression of atherosclerosis in high-risk people

Insulin glargine retards progression of atherosclerosis in high-risk people

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Dyax second quarter 2012 total revenues increase to $14.0 million

Dyax second quarter 2012 total revenues increase to $14.0 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.